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We have studied transcription factors that are coupled to the activation of cytokine receptors in liver and in mammary epithelial cells. Interleukin-6 (IL-6) causes the rapid activation of the acute-phase response factor (APRF) in the liver of animals during acute inflammation and in cultured human hepatoma cells (HepG2) and induces the transcription of the acute-phase protein genes, e.g. a,-macroglobulin (a&l).
In the mammary gland and in cultured HCll mammary epithelial cells, milk protein genes, e.g. Bcasein, are induced by the lactogenic hormones, insulin, glucocorticoids, and PRL. The induction of the 8-casein gene promoter is preceded by the activation of the mammary gland factor (MGF). We have compared the DNA binding sequences of APRF and MGF, 5'-CTTCTT/GGGAAlT-3', and have found that they coincide in 11 of 12 positions. Bandshift experiments and oligonucleotide competition experiments showed that both factors, MGF and APRF, are able to bind to the IL-6 response element of the aa-M gene promoter and to the lactogenic hormone response element of the j3-casein gene promoter with very similar specificities.
Partial proteolytic digestion of APRF and MGF DNA complexes yielded similar clipping patterns. The UV cross-linked DNA complexes of both transcription factors were of the same apparent molecular mass. IL-6 activation of APRF in HepGP cells can be observed within minutes. MGF induction by PRL in HCll cells occurs with similar kinetics. The synergistic action of glucocorticoids and PRL is necessary for the induction of the 8-casein gene, but PRL is sufficient for MGF activation. Multimers of the MGF binding site confer IL-6 inducibility to a reporter gene in transiently transfected HepG2 cells. We conclude that the IL-6 receptor in liver and the PRL receptor in the mammary gland activate very similar transcription factors. (Molecular Endocrinology 6: 469-477, 1994 )
INTRODUCTION
Cytokines and interleukins (ILs) are soluble extracellular mediators which regulate proliferation and differentiation of many cell lineages. These molecules exert pleiotropic functions and govern a wide variety of biological effects through the interaction with specific receptors expressed on the surface of target cells. The molecular characterization of the cytokine receptors has revealed a gene family. IL-2 to IL-7, as well as granulocytemacrophage colony-stimulating factor, granulocyte colony stimulating factor, erythropoietin, ciliary neurotropic factor, GH, and PRL exert their functions through members of this receptor family. The receptors share a homologous region of about 200 amino acids in their extracellular domains, characterized by four cysteine residues in the amino-terminal half and a tryptophanserine-X-tryptophan-serine motif in the carboxy-terminal half (1, 2). Many of these cytokine receptors consist of two proteins. One protein is required for ligand binding and a second associated molecule is required for the transduction of the cytoplasmic signal to the cell's interior. MOL ENDO. 1994 Vol 8 No. 4 470 IL-6 receptor, and the formation of high affinity binding sites. Binding of IL-6 to IL-6R induces disulfide-linked homodimerization of gp130 and association with a tyrosine kinase activity (5). gpl30 also serves as a signal transducer for the leukemia inhibitory factor, oncostatin M, and the ciliary neurotropic factor (6). The pleiotropic and redundant effects of cytokines may be based on the shared signal transduction molecules of their receptors (7).
PRL is a pituitary hormone with a wide range of physiological tasks. It controls cellular proliferation and differentiation in diverse cell types and is important in osmoregulation, immune-regulation, and reproduction (8). Two forms of the PRL receptor are known in the mouse. Alternative splicing leads to a long form of the PRL receptor (608 amino acids) and a short form of the PRL receptor (310 amino acids). The molecular details of PRL receptor signaling are less well known when compared with the IL-6 receptor. Associated signal transduction components have not been identified unequivocally, but the activation of a cellular tyrosine kinase seems to be an important early event upon PRL receptor triggering (9).
Signal transduction pathways originating at the cell membrane eventually result in the modulation of gene transcription in the nucleus. This step in the signal transduction pathway is mediated through the activity of transcription factors which interact with response elements in the promoter regions of sets of genes (10). The interaction of a nuclear factor present in mammary epithelial cells with a conserved promoter element of the casein gene family led to the identification of the PRL-activated mammary gland factor ( MGF). MGF was found in mammary glands of lactating animals and in hormonally stimulated HCll cells (11). HCl 1 mammary epithelial cells express milk proteins upon stimulation with the lactogenic hormones PRL, glucocorticoids, and insulin. The MGF recognition site has been mapped to the region -105 to -75 of the rat 8-casein promoter, a region essential for the promoter responsiveness to lactogenic hormones (12, 13).
The cytokine IL-6 mediates acute-phase responses in hepatocytes.
The IL-6-activated acute-phase response factor (APRF) was found to bind to a specific promoter sequence and activate gene transcription of the rat an-macroglobulin gene in rat liver (14, 15) . The acute-phase response element maps to position -176 to -161 of the rat cuz-macroglobulin gene promoter. Activation of APRF by IL-6 was also observed in the human hepatoma cell line HepG2. These cells have been used for the functional analysis of the rat LYEmacroglobulin promoter and its regulation by IL-6 (15-l 7).
The recognition sites for MGF, 5'-CTTCTTGGAATT-3', and APRF, 5'-CTTCTGGGAATT3', are identical in 11 of 12 positions. This observation and the relatedness of the IL-6 and the PRL receptors led us to compare the structural and functional activities of MGF and APRF. We report here that both factors share DNA binding specificity. Fig. 1 . The APRF is a transcription factor activated in liver as a result of inflammation and the release of IL-6. IL-6 also activates the DNA binding of APRF in the human hepatoma cell line HepG2 and participates in the transcriptional regulation of acute phase protein genes, e.g. az-macroglobulin (LYE-M). The IL-6 response element in the promoter of the an-M gene has the sequence 5'-CTTCTGGGAATT-3' (17). The MGF (Col 7) and APRF (TB2) motifs are very similar and are shown in Fig. 1 .
We investigated the possibility that both factors share their DNA binding specificity (Fig. 2) . Nuclear extracts were prepared from rat livers of control rats and rats in which an acute phase reaction had been induced by the injection of complete Freund's adjuvant. Nuclear extracts were also prepared from mammary glands of control and of lactating rats. Bandshift analyses were carried out using the MGF binding site Col 7 as a radioactive DNA probe (lanes l-4). Strong DNA complex formation was only detected when nuclear extracts from the induced tissues were introduced into the binding reaction (lanes 2 and 4). This results was confirmed with the nuclear extracts derived from the cultured cells. epithelial cells treated with PRL, reveal a similar DNA binding activity (lanes 6 and 8).
APRF and MGF Bind with Similar Specificity to Response Elements of the a2-M and the @Casein Gene Promoters
The IL-6 response of the LY~-M promoter depends on a response element located at position -153 to -170. The sequence contains the core binding site for APRF. We used a dimer of the core binding site (probe TB2 shown in Table 1 ) in our bandshift experiments. This dimer was shown to confer efficient IL-6 responsiveness to a linked reporter gene (17). Nuclear extracts from mammary glands of lactating rats and from livers of rats with acute phase reactions were incubated with radioactively labeled probe TB2 (Fig. 3A) . Both extracts form two specific complexes with this probe (lanes 1 and 5). Since the probe contains two binding sites, we suggest that the slower migrating complex contains 2 molecules of MGF or APRF and the faster migrating complex contains 1 molecule of MGF or APRF bound per molecule of DNA probe. To confirm the specificity of complex formation, binding assays were performed in the presence of a lOO-fold molar excess of nonradioactive competitor oligonucleotides. The oligonucleotide Col 7, the MGF binding site present in the @-casein gene promoter, abolished binding of the TBP-protein complex. (Fig. 3A , lanes 2 and 6). Binding was also competed by oligonucleotide Col 7.1 (lanes 3 and 7). This oligonucleotide differs from Col 7 in a single base pair (shown in Table 1 ). Efficient binding competition is also exerted by an excess of the unlabeled probe TB2 (lanes 4 and 8). Both complexes formed by MGF and APRF are specifically competed.
The same nuclear extracts were reacted with Col 7 as a radioactive probe. This probe contains only a single were incubated with the probe alone (lanes 1 and 5) or together with an excess of oligonucleotides Col 7 (lanes 2 and 6), the mutated oligonucleotide Col7.1 (lanes 3 and 7) or TB2 (lanes 4 and 8).
MOL ENDO. 1994 472 Vol8 No. 4 binding site and specific DNA complexes were formed with proteins from lactating mammary gland extracts and acute-phase liver extracts (Fig. 36, lanes 1 and 5) . Nonradioactive Col 7 served as an efficient competitor for binding (lanes 2 and 6), whereas the mutated oligonucleotide Col 7.1 was less efficient (lanes 3 and 7). Oligonucleotide TB2, derived from the acute-phase gene promoter, was found to be a good competitor (Fig. 38, lanes 4 and 8) . We observed a higher apparent binding affinity to the Col 7 probe for both nuclear extracts, although the TB2 probe contains a dimer core binding site. The lower affinity binding to TB2 might be the reason for the more efficient competition of Col7.1 with the TB2 probe. These results suggest that the DNA binding specificity of APRF and MGF is very similar.
PRL and IL-6 Trigger a Rapid, Cell Type-Specific Activation of MGF and APRF The kinetics of IL-6 induction of APRF in liver cells and PRL induction of MGF in mammary epithelial cells were cornbared. HepG2 cells were treated with IL-6 for increasing times. Nuclear extracts were prepared and the APRF activity was visualized by bandshift assays with radioactive probe Col 7 (Fig. 4) . APRF activity can be Table 1 ). Nuclear extracts were prepared from 7 shown in Table 1 ). HCl 1 cells were incubated with PRL or HepG2 cells treated for increasing times with IL-6 or PRL IL-6 for the times indicated. The cells were harvested, nuclear (lanes 3-7). The IL-6 induced complex exhibits a slightly slower extracts were prepared, and the bandshift analysis was carried mobility than that observed with tissue extracts (lanes 1 and out (lanes 2-6). Nuclear extract from lactating mammary gland 2). The specificity of the complexes marked by the arrows was used in lanes 1 and 10. Competition analysis was carried was confirmed by competition analysis (lanes 8-10). Eight out with the extract of cells treated for 25 min with PRL (lanes micrograms of nuclear protein from HepG2 cells were intro-7-9). Ten micrograms of HCll nuclear extract were added duced into the DNA binding reaction.
per DNA binding reaction.
6). PRL treatment of HepG2 cells does not cause APRF activation (lane 7)
. The specificity of the binding reaction is again confirmed by the oligonucleotide competition experiments shown in lanes 8 and 9. The APRF-specific band can be competed by an excess of nonradioactive Col 7. A faster migrating band can be seen in lanes 5, 7,8, 9, and 10. This band cannot be competed with an excess of nonradioactive Col 7 (lane 9) and is most likely due to nonspecific DNA binding.
HCll cells were treated with PRL for increasing times, nuclear extracts were prepared, and the MGF activity was determined (Fig. 5) . Low MGF activity can be detected after 5 min (lane 3) and higher levels after 15 and 25 min of PRL treatment. The treatment of HCl 1 mammary epithelial cells with IL-6 did not cause induction of MGF (lane 6). The binding specificity of MGF was ascertained by the oligonucleotide competition experiments in lanes 7-l 0. The complexes formed by the proteins derived from HepG2 cells and HCll cells migrate slightly slower than the complexes derived from the liver and the mammary gland. This observation has been described before for HCll cells and mammary gland extract (13), but its molecular basis is not known.
The (Fig. 6) . Partial proteolytic digestion of MGF and APRF DNA complexes yielded similar clipping patterns.
The similarity of MGF and APRF was further investigated and the molecular weights of both factors were compared.
For this purpose the protein-DNA complexes were cross-linked in the polyacrylamide gel used for the bandshift analysis by UV light and eluted from the gel fragments, and their molecular weights were liver(ap) The functional role of APRF and MGF in the transactivation of transcription was evaluated in transfected cells. For this purpose promoter-reporter gene constructs were constructed (Fig. 8A) . The P-casein gene promoter, truncated at position -344, has previously been shown to direct the lactogenic hormone-dependent induction of a linked CAT gene (Fig. 8A, in which a dimer of the glucocorticoid response element linked to the p-casein promoter truncated at position -105 was used as a control. This construct retains inducibility in transfected HCl 1 cells (Fig. 88) .
Hep G2 cells were transfected with the promoter constructs containing one, two, three, and four MGF binding sites and induced with IL-6. Cellular extracts were prepared and CAT activity was determined. Figure  8C shows that the construct containing a single MGF site is not inducible. The construct containing two MGF sites shows a weak IL-6 inducibility and the constructs containing three and four MGF sites show a strong IL-6 inducibility. Each additional MGF site increased the inducibility about IO-fold. These results indicate that APRF, the factor induced by IL-6 in HepG2 cells, is sufficient to cause transactivation through a MGF site.
DISCUSSION
Cytokines and their receptors regulate important physiological responses such as hematopoiesis, the immune response, and inflammation. The molecular analysis of these responses has shown that the action of different cytokines is pleiotropic and also redundant. Different cytokines can cause similar effects in individual cell types. It has been suggested that this redundancy is connected to the similarities found in the cytokine receptor structure. Several receptors consist of two polypeptides, a ligand-binding and a signal-transducing subunit. The ligand-binding subunit is cytokine specific, but the signal-transducing subunit may be shared. We have investigated the similarities between the signal pathways emanating from the PRL receptor and the IL-6 receptor at the level of nuclear transcription factors activated by these ligands.
Several transcription factors are activated by IL-6 induction in liver cells (3). The factor APRF exhibits striking similarities to MGF, a factor induced by PRL in mammary epithelial cells. Both transcription factors are targets of cytokine receptor signaling, but they are involved in independent physiological processes. We Our experiments do not yet allow conclusions about the equivalence of the receptor signaling. IL-6 and the PRL receptor activate a very similar transcription factor. The IL-6 receptor transduces its signal via a second accessory receptor, gp130. The next step of the pathway is still unknown, but tyrosine phosphorylation seems to be involved in the signal transmission. Tyrosine phosphorylation has also been observed upon PRL receptor activation, but so far only for the form of the receptor found in Nb-2 rat T lymphoma cells (9). The predominant form of the PRL receptor in liver cells is the so called short form, a form that is not able to trigger the transactivation of the P-casein gene promoter. Our receptor analyses suggest that HepG2 cells express only very little or no PRL receptor. The same is true for IL-6 receptor expression in HCl 1 cells. For this reason we cannot conclude yet whether IL-6 receptor can cause the activation of MGF and PRL the activation of APRF.
Our experiments show that PRL is sufficient for the activation of MGF in mammary epithelial cells. This observation should be viewed in the context of the hormonal requirements for p-casein gene expression. Many investigators have shown that the synergistic action of the lactogenic hormones, insulin, glucocorticoids, and PRL, are required for gene induction. The induction of MGF by PRL must be supplemented by additional hormonal events mediated by glucocorticoids and insulin before @-casein gene transcription can occur. This conclusion is supported by our studies which describe crucial regulatory elements located upstream from the MGF binding site (20, 21) . component (21). Our results could be interpreted if the counteraction of repressor action mediated by the PRL receptor and the positive activation mediated by IL-6 requires different secondary modifications of the factor. The provision of an additional MGF site to the promoter construct tested in HepG2 cells caused a lo-fold increase on promoter activity. This indicates that a multimeric binding might be necessary for transactivation.
A family of factors involved in the mediation of cytokine action on the transcriptional level has recently been described (22, 23). The interferon-(Y/P receptor causes the activation of a transcription factor complex (ISGFS) which is composed of ~113, p91, and ~84. Intet-ferony receptor confers its signal to the induced genes via the activation of p91 only. P91 becomes phosphorylated on tyrosine and assumes DNA binding activity. It binds to the interferon-y-responsive element (24, 25) . This element includes a TCNNGGAA motif. This motif is similar to the MGF and APRF binding site (26). APRF cross-reacts with an antibody raised against the 91 K protein of the ISGF3 N complex (Refs. 27 and 28 and our unpublished results). P91 also participates in the signaling through growth factor receptors with tyrosine kinase activity. Epidermal growth factor (EGF) receptor activation leads to the formation of p91 containing DNA binding complex, similar to the complex formed in HepG2 cells upon 29) . A molecular comparison of MGF to the 91 K ISGFB subunit and APRF will be of great interest.
MGF was initially discovered in mammary epithelial cells contributing to the tissue-specific expression of the @-casein gene. It is possible that MGF is not a mammary-specific factor and might have functions in other cell types. This might necessitate a more general naming of the factor in the future.
MATERIALS AND METHODS
The role of insulin and glucocorticoids might be crucial to explain the intricacies of the P-casein promoter regulation. It is still surprising to observe that the activation of MGF by PRL in HCl 1 cells is not sufficient to stimulate the transcription from the promoter constructs containing multimerized MGF sites. This is in contrast to the IL-6 activation of the same constructs in HepG2 cells. Although we do not have an explanation for this result, it might indicate a further mechanism of cytokine action. It is possible that the DNA binding activity and the transactivation activity of MGF are regulated separately by phosphorylation events; and that DNA binding activity is affected equally by the action of IL-6 and PRL wheras the transactivation activity is regulated in a cytokine-specific manner. IL-6 could cause the "positive" activation of APRF in liver cells through a particular pattern of secondary modifications. The action of MGF in mammary epithelial cells has been partially characterized as the relief of repression. We have shown that MGF counteracts a transcriptional repressor complex composed of YY-1 and a second Cell Culture
Mouse mammary epithelial (HCll) cells were grown in RPMI-1640 medium containing 10% heat-inactivated fetal calf serum, 5 pg bovine insulin/ml, 10 ng murine EGF/ml, 50 pg gentamitin/ml, and 2 mM glutamine. Hormone induction was performed by addition of 0.1 PM dexamethasone (Sigma Chemical Co, St. Louis, MO) and/or 5 pg ovine PRL (Sigma) and in the absence of EGF.
Human hepatoma (HepG2) cells were cultured in Dulbecco's modified Eagle's medium, supplemented with 10% heat inactivated fetal calf serum, 50 ng gentamycin/ml, and 2 mM glutamine. IL-6 induction was performed in medium containing 1% heat inactivated fetal calf serum and 300 U recombinant human IL-6 (Boehringer Mannheim. Mannheim, Germany) per ml.
Animals
Mammary glands were removed from lactating and postlactating rats after the animals were killed by cervical dislocation. Acute-phase reaction was induced in adult rats by ip injection of 0.15 ml complete Freund's adjuvant per 100 g body wt; 16 h later the liver was removed. Tissues were used directly for 10% glycerol] by gentle inversion for 1 h at 4 C. After centrifugation for 5 min at 10,000 x g, the supernatant was removed-and dialyzed twice for 96 min against 250 ml dialysis buffer (25 mM HEPES pH 7.6, 40 mM KCI, 1 mM DTT, 10% glycerol).
Aliquots were frozen in liquid nitrogen and stored at -70 C.
Nuclear
Extracts from Cultured HepG2 and HCll Cells
After being washed twice with PBS, 10' cells were scraped into a small volume of PBS and centrifuged at 1,000 x g ior 5 min. The cell pellet was resuspended ina hypotonic buffer (20 mM HEPES oH 7.6, 10 mM KCI. 1 mM MqC&, 0.5 mM DTT, 0.1% Triton x-100, 20% glycerol, 5 pg/ml aprotinin, 5 pg/ml leupeptin, 2 pg/ml pepstatin, 2 mM phenylmethylsulfonylfluoride).
Cells were lysed by 20 strokes in a glass Dounce homogenizer.
The homogenate was centrifuged at 2,000 x g for 5 min and the pelleted nuclei were extracted in a hypertonic buffer (containing 0.3 M NaCI) and gently inverted for 20 min at 4 C. The extract was centrifuged at 10,000 x g for 10 min. Aliquots of the supernatant were frozen in liquid nitrogen and stored at -70 C. The DNA-protein complexes were formed as described for EMSA. After 20 min, proteases were added as indicated. The proteolytic digestion was allowed to proceed for 10 min before the separation of the partially digested complexes on a polyacrylamide gel.
UV Cross-Linking Synthetic oligonucleotides were labeled as described. Instead of deoxythymidine triphosphate, 5-bromo-2'-deoxyuridine-5'-triphosphate (BrdU) was used in the fill-in reaction. EMSA was performed with the BrdU and with a deoxythymidinecontaining probe as control. The acrylamide gel was irradiated for 10 min with UV light and autora&ographed for 1 h. Gel slices corresoondina to the orotein-DNA complex of MGF and APRF were i&ubat& in SDS sample buffer and subjected to electrophoresis on a 8% SDS-polyacrylamide gel. The gel was dried and autoradiographed.
